A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD

Kidney International

Volumn 68, Issue 6, 2005, Pages 2846-2856

  Van Wyck, David B ^a   Roppolo, Michael ^b   Martinez, Carlos O ^b   Mazey, Richard M ^b   McMurray, Stephen ^b  

^a Kidney Health Institute LLC   (United States)

^b NONE

Author keywords

Anemia; CKD; Iron; Iron deficiency; Iron sucrose

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BURNING SENSATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VOMITING;

ADMINISTRATION, ORAL; AGED; ANEMIA; ERYTHROPOIESIS; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 32844465284     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00758.x     Document Type: Article

References (19)

1. NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001
2. Guidelines for the management of anaemia in chronic renal failure. Section III. Treatment of renal anaemia. Nephrol Dial Transplant 19:II16-II31, 2004
3. STOVES J, INGLIS H, NEWSTEAD CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:967-974, 2001
4. CHARYTAN C, QUNIBI W, BAILIE GR: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100:c55-c62, 2005
5. AGGARWAL HK, NAND N, SINGH S, et al: Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51:170-174, 2003
6. ARONOFF GR: Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol 15(Suppl 2):S99-106, 2004
7. HSU CY, MCCULLOCH CE, CURHAN GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13:2783-2786, 2002
8. COLLINS AJ, KASISKE B, HERZOG C, et al: Excerpts from the United States Renal Data System 2004 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 45:S8-S270, 2005
9. WARE JE: SF-36® Health Survey (SF-36 Standard, US version 1.0), Lincoln, RI, USA, Medical Outcomes Trust and Quality Metric Incorporated, 2002
10. KLAHR S: Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int 49:1783-1786, 1996
11. KOOISTRA MP, NIEMANTSVERDRIET EC, VAN ES A, et al: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13:82-88, 1998
12. KOOISTRA MP, MARX JJ: The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 13:2578-2582, 1998
13. SKIKNE BS, AHLUWALIA N, FERGUSSON B, et al: Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 135:452-458, 2000
14. FEHR T, AMMANN P, GARZONI D, et al: Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66:1206-1211, 2004
15. ZAGER RA, JOHNSON AC, HANSON SY: Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int 66:144-156, 2004
16. AGARWAL R, VASAVADA N, SACHS NG, CHASE S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289, 2004
17. VAN WYCK DB: Labile iron: Manifestations and clinical implications. J Am Soc Nephrol 15(Suppl 2):S107-S111, 2004
18. VAN WYCK DB, ANDERSON J, JOHNSON K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 19:561-563, 2004
19. SLOAND JA, SHELLY MA, ERENSTONE AL, et al: Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Perit Dial Int 18:522-527, 1998